Murine leukemia virus vector integration favors promoter regions and regional hot spots in a human T-cell line
- 8 May 2006
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 345 (3), 1099-1107
- https://doi.org/10.1016/j.bbrc.2006.05.007
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Oncogenesis Following Delivery of a Nonprimate Lentiviral Gene Therapy Vector to Fetal and Neonatal MiceMolecular Therapy, 2005
- Clonal Dominance of Hematopoietic Stem Cells Triggered by Retroviral Gene MarkingScience, 2005
- Retroviral DNA Integration: ASLV, HIV, and MLV Show Distinct Target Site PreferencesPLoS Biology, 2004
- LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1Science, 2003
- Transcription Start Regions in the Human Genome Are Favored Targets for MLV IntegrationScience, 2003
- HIV-1 Integration in the Human Genome Favors Active Genes and Local HotspotsCell, 2002
- Murine Leukemia Induced by Retroviral Gene MarkingScience, 2002
- Gene therapy of severe combined immunodeficienciesThe Journal of Gene Medicine, 2001
- Successful Peripheral T-Lymphocyte–Directed Gene Transfer for a Patient With Severe Combined Immune Deficiency Caused by Adenosine Deaminase DeficiencyBlood, 1998
- A Model for Predicting the Risk of Cancer Consequent to Retroviral Gene TherapyHuman Gene Therapy, 1992